A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections

Trial Profile

A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Dalbavancin (Primary) ; Aztreonam; Cefadroxil; Clindamycin; Flucloxacillin; Metronidazole; Metronidazole; Oxacillin; Vancomycin
  • Indications Bacterial infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Durata Therapeutics
  • Most Recent Events

    • 06 Jun 2017 Planned End Date changed from 1 Jul 2018 to 25 Jan 2019.
    • 06 Jun 2017 Planned primary completion date changed from 1 Apr 2018 to 25 Jan 2019.
    • 06 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top